A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

GW572016 (lapatinib)

tyrosine kinase inhibitor

Trial Locations (31)

10960

GSK Investigational Site, Nyack

19140

GSK Investigational Site, Philadelphia

20007

GSK Investigational Site, Washington D.C.

27707

GSK Investigational Site, Durham

32610

GSK Investigational Site, Gainsville

35501

GSK Investigational Site, Jasper

37203

GSK Investigational Site, Nashville

44106

GSK Investigational Site, Cleveland

60007

GSK Investigational Site, Elk Grove Village

70006

GSK Investigational Site, Metairie

70360

GSK Investigational Site, Houma

77030

GSK Investigational Site, Houston

78412

GSK Investigational Site, Corpus Christi

87505

GSK Investigational Site, Santa Fe

90813

GSK Investigational Site, Long Beach

92037

GSK Investigational Site, La Jolla

92064

GSK Investigational Site, Poway

92270

GSK Investigational Site, Rancho Mirage

97213

GSK Investigational Site, Portland

94904-2007

GSK Investigational Site, Greenbrae

03756

GSK Investigational Site, Lebanon

08901

GSK Investigational Site, New Brunswick

27599-7600

GSK Investigational Site, Chapel Hill

T2N 4N2

GSK Investigational Site, Calgary

T6G 1Z2

GSK Investigational Site, Edmonton

K7L 5P9

GSK Investigational Site, Kingston

N2G 1G3

GSK Investigational Site, Kitchener

K1H 1C4

GSK Investigational Site, Ottawa

M5G 2M9

GSK Investigational Site, Toronto

J4V 2H1

GSK Investigational Site, Greenfield Park

G6V 3Z1

GSK Investigational Site, Lévis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY